}lomogenates of testes from human fetuses of 12-16 weeks gestation were incubated in vitro with pregnenolone-4-14C and pregnenolone-7-3H-sulfate.
INTRODUCTION
Steroid sulfates are present in relatively large quantities in the human fetal circulation (i).
Steroid sulfokinase activity has been demonstrated both in vivo and in vitro in the human fetal adrenal (2-5).
Normal adult human testes possess this capacity as well (6,7).
Neutral steroid sulfate secretion by normal human adult testes has been demonstrated recently (8).
Although the metabolism of certain unconjugated steroids by human fetal testes has been studied (9-11), the metabolism of steroid sulfates by this tissue has not.
Since steroid sulfates can be transformed to other steroid sulfates as well as to biolo~ically active hormones in both the fetus and the adult (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) , it was felt of interest to study in_vitro the metabolic fate of pregnenolone5 and pregnenolofie sulfate (PS) in human fetal testes.
MATERIALS AND METHODS
Human fetal testes were obtained from 3 fetuses of 12-16 weeks gestation at the time of hysterotomy for therapeutic termination of pregnancy.
A segment of testis was removed from each fetus for histologic examination.
Testicular tissue, weighing 17.6 mg from one fetus (crown-rump and crown-heel lengths of 75 mm and 102 mm respectively), used in incubation I was homogenized and immediately incubated, while testicular tissue weighing 43 mg from the two remaining fetuses (crown-rump and crown-heel lengths of one 86 mm and 125 mm respectively, and of the other 93 mm and 138 mm respectively), used in incubation 2, was frozen at -70°C in liquid nitrogen and thawed immediately prior to homogenization and incubation.
Tissues were homogenized in an all glass Potter-ElvehJem apparatus.
Materials:
Radioactive steroids were obtained from New England Nuclear Co. Pregnenolone-4-14C, specific activity (SA) 56 mCi/mmole (lot 236-75A-14) was purified by thin layer chromatography (TLC) in systems i and 2 (Table I) . Pregnenolone-7-3H-sulfate, was purified by Cellte column partition chromatography (CPC) in system 3 and paper chromatography (PC) in system 4. Pregnenolone-7-3H-sulfate-35S was prepared by combining pregnenolone-7-3H-sulfate and pregnenolone sulfate-35S, (SA 12 mCi/mmole, lot 523004). The double labeled PS was purified in systems 3 and 4 and partitioned prior to use between organic solvent and water to remove unconjugated steroid.
All organic solvents were analytical grade and redistilled prior to use. Crystalline steroids used as standards and carriers were obtained commercially and assessed for purity by recrystallization, chromatographic behavior and melting point determination before use. Co-factors were purchased from Sigma Chemical Co.
The interconversion between ammnnium and pyridinium salts of steroid sulfates was accomplished by the method of McKenna and Norymberski (24) .
Incubation i: The homogenized tissue was incubated in a medium containing 1.74 ml of 0.15 M phosphate buffer pH 7.4, 1.8 ~Ci pregnenolone -4-14C, i0 ~Ci pregnenolone-7-N-sulfate, 1.49 ~moles ATP, 1.13 ~moles DPN, 1.01 ~moles TPN, 3.96 ~moles DL-isocltric acid and 200 ~g isocitric dehydrogenase.
Two drops of propylene glycol were added to dissolve the preguenolone-4-14C.
The incubation was carried out in a Dubnoff metabolic incubator at 37oc for 3 hours using 95% 02 and 5% C02 as the gas phase. The reaction was stopped by the addition of dichloromethane, and the material was then partitioned between dichloromethane and water.
Incubation 2: The homogenized tissue was added to a flask containinR pregnenolone-7-38-sulfate-35S (2936 x 104cpm 3H and 2343 x 103 cpm 355).
The incubation medium contained Krebs-Ringer bicarbonate buffer, 2.98 ~moles ATP, 2.26 Nmoles DPN~ 2.02 ~moles TPN, 7.92 ~moles DL-isocitric acid and 400 ~IF isocitric dehydrogenase.
The ratio of tissue (mg) to buffer (ml) was 20/1.
Three tissueless control flasks and 2 inactivated tissue control flasks were prepared in a similar manner, but with 0.002 x the amount of PS. All flasks were incubated simultaneously in a Dubnoff metabolic incubator at 37°C for 3 hours using air as the gas phase.
The reaction was stopped by the addition of i0 ml of dichloromethane to each flask.
Following extraction, the material from each flask was submitted to purification by CPC in system 3 without prior partition into conjugated and unconjugated fractions. Isolation and identification of metabolites were performed using reverse isotope dilution techniques which included identical chromatographic behavior of the radioactive material and the steroid carrier under study in various chromatographic systems and successive recrysta]-lization until crystals and mother liquor agreed within 5% and were witllin 5v of mean value.
Chromat0g_raphv:
CPC usin~ Johns-Manville Celite No. 545, previously washed as described by Kelly et al (25) , as the support and PC using ~hatman No. i paper were performed as previously described (22) .
Thin layer chromatography (TLC) was carried out on silica gel G (Merck & Co., Darmstadt) as described by Lisboa and Diczfalusy (26) . The systems used are listed in Table i and will be referred to in the text by number.
Estimation of Steroids:
The identification of non-radioactive sam~ies--has been des-c¥i-bed previously (23) .
Polar material was dissolved in I ml methanol and 0.i ml of solubilizer (Nuclear Chicago Corp.) prior to the addition of the scintillation medium. Quench corrections were performed using an internal standard technique.
3H-and 14C-activity were expressed as dpm.
35S-activity is expressed as cDm after correcting for decay.
Thin layer and paper chromatoRrams were scanned on a Packard radiochromatogram scanner Model 7200.
Derivative formation was performed when sufficient material was available.
Solvolysis was carried out using the method of Segal et al (27) .
Acetylation using acetic anhydride and anhydrous pyridine (1:2) was carried out at room temperature overnight. Saponification was accomplished by the method of Neher et al (28) . 94.4% of the recovered 3H-labeled material and 1.2% of the recovered 14C-labeled material were found in the aqueous fraction. However, after PC in system 4, 5 zones of radioactivity were observed, all of which contained only the tritium label. All of the 14C-labeled material migrated to the solvent front and was found to be pre~nenolone.
RESULTS
Zone i (Rf=0.80):
The radioactive material in this zone behaved in a similar fashion to carrier PS. This material was solvolyzed and submitted to PC in system 5. Two peaks were identified (Rf=0.45 and 0.02). The less polar area, which behaved llke prep, nenolone,
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was rerun in system 5 after authentic pregnenolone carrier was added.
Both radioactive and crystalline material exhibited identical mobility. It was concluded that this radioactive material represented unconverted substrate.
The more polar area was submitted to PC in system 6. The major peak of radioactivity (Rf=0.90) was acetylated and run in system 7.
An area similar to 5-pregnene-3~20~-diol diacetate (pregnenediol diacetate) (Rf=0.85) was identified. A portion of this material was submitted to countercurrent distribution (CCD) in system 8, A single peak (K=6.69) was observed associated with authentic carrier pregnenediol diacetate. After additional carrier was added, the radioactive material was recrystallized to constant SA (Table 2) .
Zone 2 (Rf=0.64): This area was similar to 17~-hydroxypregnenolone sulfate (17~-OH-PS). However, following solvolysis and chromatography in several systems, the identity of this metabolite could not be established definitely.
Zone 3 (Rf=0.46): A portion of the radioactive material from this zone, which behaved like dehydroepiandrosterone sulfate (DHAS), was solvolyzed.
After the addition of authentic dehydroepiandrosterone (DHA) carrier, this material was submitted to PC in system 7 for 50 hours, and both radioactive and added crystalline material had identical mobilities (Rt=0.32).
The material was then submitted to PC in system 9 and the mobilities of carrier and radioactive material were again identical (Rf=0.57).
The material was mixed with additional authentic DHA and recrystallized to constant SA as the unconjugated compound (Table 2) . Pregnenolone and androstenedione were tentatively identified.
From the experimental flask, areas of radioactivity were noted in HBV IV to VI and HBV X to XII. The largest (HBV IV to VI) corresponded in mobility to carrier PS. The mobility of the radioactive material in the other area (HBV X to XIII), corresponded to carrier 17~-OH-PS and DHAS. After conversion to the pyridinium salt, the PS-like material was submitted to CPC in system i0. The area (HBV II to III) corresponding to carrier PS was submitted to PC in system 4 and behaved in an identical manner to PS. This material was recrystallized to constant SA after further addition of crystalline PS (Table 4) . The area corresponding to 17a-OH-PS and DNAS was submitted to CPC in system i0. Four zones of radioactivity were isolated. Zone I (HBV VIII to X) was resubmitted to CPC in system 3. Two areas of radioactivity were found. The less polar (HBV IX and X) was identical to carrier 17a-ON-PS and, after further addition of cold carrier, was recrystallized to constant SA (Table 4) .
Zone 2 (HBV IV to VI) was solvolyzed and submitted to PC in system 4. An area similar to DHAS carrier was rechromatographed in system 4 after authentic DHAS carrier had been added. This material was solvolyzed and submitted to PC in system 9. A small peak of radioactivity with a mobility identical to carrier DHA was noted, but the small amount of radioactivity precluded definitive identification.
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The remaining two zones of polar radioactive material (HBV I and HBV II to III) were investigated further buc the identity of this material could not be established.
DISCUSSION
The demonstration in the first incubation that approximately 6% of the recovered tritium was in the organic fraction suggests the presence of sulfatase activity. The 3H/14C ratios of the unconJugated C-21 and C-19 steroids identified (Table 3) are noted to vary, but both labels are present in the final recrystallization of each metabolite indicating that both conjugated and unconjugated pregnenolone served as precursors in the formation of these unconjugated metabolites.
The inconsistency in the 3H/14C ratios derived from the recrystallization data for 17a-hydroxypregnenolone and 17~-hydroxyprogesterone cannot be explained readily. Sulfatase activity was demonstrated in the second incubation as well, albeit to a lesser degree.
Sulfatase activity has been found in placenta (29,30), human fetal adrenals near term (29), and adult testes (23, 31) . That fetal perfusion studies have failed to demonstrate sulfatase activity may be explained either by the inability of the steroid sulfate to gain entrance to the site of enzyme action or by the fact that whole body perfusions were performed and the activity of any one organ, particularly one which may contribute quantitatively small amounts to the total steroid pool, may be difficult to assess. In the second incubation, the direct conversion of pregnenolone 3 35 -3H-sulfate-35S to 17~-hydroxypregnenolone-H-sulfate-S has been demonstrated.
Conversion of PS, which is present in large amounts in the umbilical artery (1) , to 17~-OH-PS, DHAS, and 16~-hydroxydehydroepiandrosterone sulfate has been demonstrated in a similar fetal adrenal incubation in this laboratory (22) . The importance of steroid sulfates in other tissues as precursors of other steroid sulfates (12) (13) (14) (15) (16) 21, 35) as well as biologically active hormones (17-20) has been noted. Steroid sulfates may play similar important roles in the fetal testis.
The work of Jost (36) has offered convincing evidence that androgens are necessary for the development and differentiation of the internal and external genitalia in the male fetus. Since in the fetal circulation steroids are present largely as sulfates, sulfatase activity in the fetal testis as demonstrated in this study may play a significant role in the biogenesis of free, biologically active androgens for this purpose.
